Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin
ConclusionSevere anemia was not uncommon during sofosbuvir plus ribavirin therapy for chronic hepatitis C genotype 2 patients. Careful monitoring of anemia is necessary in patients with chronic kidney disease and low baseline hemoglobin level and platelet count.
Source: Journal of the Formosan Medical Association - Category: General Medicine Source Type: research
More News: Anemia | Cancer & Oncology | Carcinoma | Chronic Kidney Disease | General Medicine | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | Liver Cancer | Toxicology | Urology & Nephrology | Virology